Combined effect of NAT2, MTR and MTHFR genotypes and tobacco on bladder cancer susceptibility in Tunisian population

Cancer Epidemiology

Volumn 32, Issue 5-6, 2009, Pages 395-402

  Ouerhani, Slah ^a   Rouissi, Kamel ^a   Marrakchi, Raja ^a   Ben Slama, Mohamed R ^b   Sfaxi, Mohamed ^b   Chebil, Mohamed ^b   ElGaaied, Amel Benammar ^a  

^a FACULTÉ DES SCIENCES DE TUNIS   (Tunisia)

^b CHARLES NICOLLE HOSPITAL   (Tunisia)

Author keywords

Bladder; Methionine synthase (MTR); Methylenetetrahydrofolate reductase (MTHFR); N acetyl transferases 2 (NAT2); Susceptibility; Tunisia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACYLTRANSFERASE; METHIONINE SYNTHASE; N ACETYL TRANSFERASE 2; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BLADDER CANCER; CANCER EPIDEMIOLOGY; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DNA METHYLATION; ENZYME ACTIVITY; FEMALE; FOLATE METABOLISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; TOBACCO;

5-METHYLTETRAHYDROFOLATE-HOMOCYSTEINE S-METHYLTRANSFERASE; AGED; ARYLAMINE N-ACETYLTRANSFERASE; CASE-CONTROL STUDIES; DNA METHYLATION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; RISK FACTORS; SMOKING; TUNISIA; URINARY BLADDER NEOPLASMS;

EID: 66149101688     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2009.04.005     Document Type: Article

References (45)

1. Silverman D.T., Rothman N., Devesa S.S., Syrigos K.N., and Skinner D.G. Bladder cancer: biology, diagnosis and management (1999), Oxford University Press, New York, NY pp. 11-55
2. Parkin D.M., Steinitz R., Khlat M., Kaldor J., Katz L., and Young J. Cancer in Jewish migrants to Israel. Int J Cancer 45 (1990) 614-621
3. Parkin D.M., Whelan S., Ferlay J., Leppo L., and Thomas D.B. Cancer incidence in five continents (2002), IARC Publication, Lyon, France
4. Sellami A., Jlidi R., Hsaïri M., and Achour N. Registre du cancer du sud Tunisie 1997. Hôpital Habib Bourguiba 2 (2000) 32-35
5. Brennan P., Bogillot O., Cordier S., Greiser E., Schill W., Vineis P., et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer 86 2 (2000) 289-294
6. Zeegers M.P., Kellen E., Buntinx F., and van den Brandt P.A. The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World J Urol 21 6 (2004) 392-401
7. Probst-Hensch N.M., Bell D.A., Watson M.A., Skipper P.L., Tannenbaum S.R., Chan K.K., et al. N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels. Cancer Epidemiol Biomarkers Prev 9 6 (2000) 619-623
8. Rosenblatt D. Clinically important genes: methylenetetrahydrofolate reductase. Clin Invest Med 24 (2001) 56-59
9. Robien K., and Ulrich C.M. 5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: a HuGE mini-review. Am J Epidemiol 157 (2003) 571-582
10. Badawi A.F., Hirvonen A., Bell D.A., Lang N.P., and Kadlubar F.F. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res 55 22 (1995) 5230-5237
11. Hein D.W., Doll M.A., Fretland A.J., Leff M.A., Webb S.J., Xiao G.H., et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 9 1 (2000) 29-42
12. Blum M., Grant D.M., McBride W., Heim M., and Meyer U.A. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 9 (1990) 193-203
13. Hein D.W. N-acetyltransferase 2 genetic polymorphism. Effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 25 11 (2006) 1649-1658
14. Hein D.W. Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta 948 1 (1988) 37-66
15. Marcus P.M., Vineis P., and Rothman N. NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population. Pharmacogenetics 10 2 (2000) 115-122
16. Garcia-Closas M., Malats N., Silverman D., Dosemeci M., Kogevinas M., Hein D.W., et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366 9486 (2005) 649-659
17. Laird P.W., and Jaenisch R. The role of DNA methylation in cancer genetic and epigenetics. Annu Rev Genet 30 (1996) 441-464
18. Shannon S., Gnanasampanthan S., Beilby J., and Iacopetta B. A polymorphism in the methylenetetrahydrofolate reductase gene predisposes to colorectal cancers with microsatellite instability. Gut 50 (2002) 520-524
19. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10 (1995) 111-113
20. Chen J., Ma J., Stampfer M.J., Palomeque C., Selhub J., and Hunter D.J. Linkage disequilibrium between the 6774T and 1298A>C polymorphisms in human methylenetetrahydrofolate reductase gene and their contributions to risk of colorectal cancer. Pharmacogenetics 12 (2002) 339-342
21. Lin J., Spitz M.R., Wang Y., Schabath M.B., Gorlov I.P., Hernandez L.M., et al. Polymorphisms of folate metabolic genes and susceptibility to bladder cancer: a case-control study. Carcinogenesis 25 (2004) 1639-1647
22. Heijmans B.T., Boer J.M., Suchiman H.E., Cornelisse C.J., Westendorp R.G., Kromhout D., et al. A common variant of the methylenetetrahydrofolate reductase gene (1p36) is associated with an increased risk of cancer. Cancer Res 63 (2003) 1249-1253
23. Karagas M.R., Park S., Nelson H.H., Andrew A.S., Mott L., Schned A., et al. Methylenetetrahydrofolate reductase (MTHFR) variants and bladder cancer: a population-based case-control study. Int J Hyg Environ Health 208 (2005) 321-327
24. Kimura F., Florl A.R., Steinhoff C., Golka K., Willers R., Seifert H.H., et al. Polymorphic methyl group metabolism genes in patients with transitional cell carcinoma of the urinary bladder. Mutat Res 458 (2001) 49-54
25. Knowles M.A. The genetics of transitional cell carcinoma: progress and potential clinical application. Br J Urol Int 84 (1999) 412-427
26. Leclerc D., Campeau E., Goyette P., Adjalla C.E., Christensen B., Ross M., et al. Human methionine synthase: c DNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet 5 (1996) 1967-1974
27. Florl A.R., Loewer R., Schmitz-Dräger B.J., and Schulz W.A. DNA methylation and expression of L1 LINE and HERV-K provirus sequences in urothelial and renal cell carcinoma. Br J Cancer 80 (1999) 1312-1321
28. Sambrook J., Fritsch E.F., and Maniatis T. Molecular cloning: a laboratory manual. 2nd edition (1989), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
29. Paz M.F., Avila S., Fraga M.F., Pollan M., Capella G., Peinada M.A., et al. Germ-line variants in methyl-group metabolisms genes and susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer Res 62 (2002) 4519-4524
30. Oliveira E., Alves S., Quental S., Ferreira F., Norton L., Costa V., et al. The MTHFR C677T and A1298C polymorphisms and susceptibility to childhood acute lymphoblastic leukemia in Portugal. J Pediatr Hematol Oncol 27 (2005) 425-429
31. Hsieh F.I., Pu Y.S., Chern H.D., Hsu L.I., Chiou H.Y., and Chen C.J. Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer. Br J Cancer 81 3 (1999) 537-541
32. Vastis K.P., Weber W.W., Bell D.A., Dupret J.M., Evans D.A.P., Grant D.M., et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 5 (1995) 1-17
33. Fukino K., Sasaki Y., Hirai S., Nakamura T., Hashimoto M., Yamagishi F., et al. Effect of N-acetyltransferase 2(NAT2), CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients. J Toxicol Sci 33 (2008) 187-195
34. O'Gorman T.W., and Woolson R.F. The effect of category choice on the odds ratio and several measures of association in case-control studies. Commun Stat 22 (1993) 1157-1171
35. Hoover R., and Cole P. Population trends in cigarette smoking and bladder cancer. Am J Epidemiol 94 5 (1971) 409-418
36. Wynder E.L., and Goldsmith R. The epidemiology of bladder cancer: a second look. Cancer 40 3 (1977) 1246-1268
37. Ouerhani S., Oliveira E., Marrakchi R., Ben Slam M.R., Sfaxi M., Ayed M., et al. Methylenetetrahydrofolate reductase and methionine synthase polymorphisms and risk of bladder cancer in a Tunisian population. Cancer Genet Cytogentics 176 (2007) 48-53
38. Ameen G., Irani-Hakime N., Fawaz N.A., Mahjoub T., and Almawi W.Y. An Arab selective gradient in the distribution of factor VG1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T. J Thromb Haemost 3 (2005) 2126-2127
39. Mtiraoui N., Ezzidi I., Chaieb M., Marmouche H., Aouni Z., Chaieb A., et al. MTHFR C677T and A1298C gene polymorphisms and hyperhomocysteinemia as risk factors of diabetic nephropathy in type 2 diabetes patients. Diabetes Res Clin Pract 75 (2007) 99-106
40. Khedhaier A., Hassen E., Bouaouina N., Gabbouj S., Ben Ahmed S., and Chouchane L. Implication of xenobiotic metabolizing enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma. BMC Cancer 8 (2008) 109-121
41. Bell D.A., Taylor J.A., Butler M.A., Stephens E., Wiest J., Brubaker L., et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 14 (1993) 1689-1692
42. McGrath M., Michaud D., and De Vivol I. Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women. BMC cancer 6 (2006) 239-247
43. Risch A., Wallace D.M.A., Bathers S., and Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 4 (1995) 231-236
44. Brockmöller J., Cascorbi I., Kerb R., and Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferase Ml and Tl, microsomal epoxide hydrolase and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 56 (1996) 3915-3925
45. Steinmaus C., Nunez S., and Smith A.H. Diet and bladder cancer: a meta-analysis of six dietary variables. Am J Epidemiol 151 (2000) 693-702